The medicinal-chemistry programme that produced cagrilintide, described by Kruse and colleagues in the Journal of Medicinal Chemistry in 2021, addressed this by re-engineering the amylin backbone with structural elements borrowed from calcitonin (a related, non-aggregating peptide) and attaching a fatty-acid side chain that enables reversible binding to serum albumin [1]
Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis
They could adjust therapy based on a patient's response instead of leaving people to navigate peptide use through Reddit, AI, and other unqualified sources
No completed Phase III trials appear in ClinicalTrials.gov for parenteral BPC-157 in any indication as of the date of this monograph
Strategies for building and maintaining good habits [56:45]
BPC-157 stands for Body Protection Compound 157, a chain of 15 amino acids derived from a protective protein found in the human digestive tract